03/22/23 2:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023RELIEF THERAPEUTICS Holding SA (SIX: RLF)( OTCQB: RLFTF)( OTCQB: RLFTYRHEA-AIneutral
03/17/23 6:25 PMOTC : RLFTF, RLFTY conferencesRelief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual MeetingRELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) ("ReliefRHEA-AIneutral
03/16/23 2:20 AMOTC : RLFTF, RLFTY Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in EuropeRELIEF THERAPEUTICS Holding SA (SIX: RLF)( OTCQB: RLFTF)( OTCQB : RLFTY ) ("Relief Therapeutics" or theRHEA-AIneutral
03/15/23 2:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVAAcer Therapeutics reports OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 Acer also announces results from a survey designed to quantify treatmentRHEA-AIneutral
02/28/23 1:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE BarsRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RHEA-AIneutral
02/14/23 1:30 AMOTC : RLFTF, RLFTY clinical trialRelief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis BullosaRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(ORCQB: RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare diseases,RHEA-AIneutral
02/08/23 1:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Provides an Update on its Financing StrategyRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) (Relief Therapeutics), today provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statement on Form F-1 initially filed withRHEA-AIneutral
01/17/23 1:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell LymphomRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) (Relief), a biopharmaceutical company identifying, developing and commercializing novel, patent protected products in select specialty, rare and ultra-rare disease areas,RHEA-AIneutral
12/27/22 2:00 AMOTC : RLFTF, RLFTY Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange CommissionRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) (Relief), announced today that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and ExchangeRHEA-AIneutral
12/20/22 1:30 AMOTC : RLFTF, RLFTY Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsRELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, todayRHEA-AIneutral
